Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, surgical-products specialist Stryker (NYSE:SYK) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Stryker's business, and see what CAPS investors are saying about the stock right now.

Stryker facts

Headquarters (founded)

Kalamazoo, Mich. (1941)

Market Cap

$16.31 billion

Industry

Health-care equipment

TTM Revenue

$6.69 billion

Management

CEO Stephen MacMillan (since January 2005)
CFO Curt Hartman (since April 2009)

Return on Equity (average, last three years)

20.4%

Dividend Yield

1%

Competitors

Zimmer Holdings (NYSE:ZMH)
Johnson & Johnson (NYSE:JNJ)

CAPS members bullish on SYK also bullish on

General Electric (NYSE:GE)
Apple (NASDAQ:AAPL)

CAPS members bearish on SYK also bearish on

Biogen Idec (NASDAQ:BIIB)
Google (NASDAQ:GOOG)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 1,236 of the 1,268 members who have rated Stryker -- some 97.5% -- believe the stock will outperform the S&P 500 going forward. These bulls include mtinvest and All-Star MattH42004, who is ranked in the top 1% of our community.

In April, mtinvest seemed stunned over Stryker's valuation: "ROE in the twenties, strong cash flow and steady growth in shareholder equity. Why is this company so cheap? I don't see orthopaedic products going out of fashion anytime soon."

In a pitch from January, MattH42004 elaborates on the long-term trends working in Stryker's favor:

When it comes to Stryker there's a lot for any investor to like. With the uncertainty in the financial markets, maybe the best thing the company has going for it is one of the strongest balance sheets in the entire health care industry. ... Stryker also has tremendous management... that has led to consistent 10% revenue growth and strong yearly cash flows. The company also has demographics on its side. An aging population is in continual need for Stryker's orthopedic products, and any form of increased government health care will only increase the demand for these products. Long term, Stryker is a solid buy below 50, and a steal below 40.

What do you think about Stryker, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Stryker is a Motley Fool Inside Value pick. Apple and Biogen are Stock Advisor selections. Johnson & Johnson is an Income Investor choice, and Google is a recommendation of Rule Breakers. The Fool owns shares of Stryker. The Fool's disclosure policy always gets a perfect score.